Skip to main content

AYTU

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

AYTU Price
Price Chart

Forward-looking statistics

Beta
0.35
Risk
58.59%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees131
Market cap$16.9M

Fundamentals

Enterprise value$17.8M
Revenue$81.7M
Revenue per employee—
Profit margin2.01%
Debt to equity64.54

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.49
Dividend per share—
Revenue per share$13.64
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$661K
Put-call ratio—

Macro factor sensitivity

Growth—
Credit—
Liquidity—
Inflation—
Commodities—
Interest Rates—

Valuation

Dividend yield0.00%
PEG Ratio5.68
Price to sales0.26
P/E Ratio5.68
Enterprise Value to Revenue0.22
Price to book0.42

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day—
Ex. dividend day—

News

Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Aytu BioPharma Inc. (AYTU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Investment Research (March 6, 2023)
Recap: Aytu BioPharma Q4 Earnings

Aytu BioPharma(NASDAQ:AYTU) stock fell by 8.33% on Tuesday after the company reported its Q4 earnings results on Monday, September 27, 2021 at 04:01 PM. Here's what investors need to know about the announcement.

Benzinga (September 29, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free